TwoStep Therapeutics develops novel modalities to enhance the efficacy and expand the applicability of targeted cancer therapies. The company focuses on engineering drug conjugates designed for improved systemic delivery and tumor penetration. This approach aims to increase therapeutic windows for precision oncology treatments.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Effective drug delivery to solid tumors remains a significant challenge in oncology due to the dense tumor microenvironment and limited accessibility of therapeutic agents. Traditional cancer therapies often lack specificity, leading to systemic toxicity and reduced efficacy in targeting tumor cells.
Solution
TwoStepTx is developing a modular drug delivery platform designed to enhance the targeting of solid tumors with various therapeutic payloads. The core technology utilizes a unique integrin-binding agent to selectively target tumor cells and the surrounding microenvironment. This targeted approach aims to improve drug distribution within the tumor, increasing the concentration of the therapeutic agent at the site of action while minimizing off-target effects. The modular design allows for the delivery of a wide range of therapeutic payloads, including chemotherapeutics, immunotherapies, and gene therapies, offering flexibility in treatment strategies. By improving drug penetration and reducing systemic toxicity, TwoStepTx seeks to enhance the efficacy and safety of cancer treatments.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing and improving targeted cancer therapies for solid tumors.
Features
- Integrin-binding agent for targeted delivery to solid tumors
- Modular design adaptable to various therapeutic payloads
- Enhanced drug distribution within the tumor microenvironment
- Reduced systemic toxicity through targeted delivery